Comparing Diabetes Medications Where Do We Set the Bar?
News Wednesday, April 2nd, 2014JAMA: March 2014
More than 25 million Americans have type 2 diabetes mellitus and face decisions about which medications to use to lower glucose levels. These decisions are increasingly complex (now involving 12 different classes of glucose-lowering agents) and increasingly costly (resulting in over $18 billion in annual expenditures1). Yet, despite the enormous health and economic implications of these decisions, there are few comparative effectiveness outcomes studies to guide clinical practice. The major goals of glycemic control in type 2 diabetes are to prevent severe hyperglycemia and to reduce the risk of long-term diabetic complications, with the majority of the effort devoted to the latter. Read More